Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status? ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1, 12.2008
- Creator
-
Rubio, R.
- Contributor
-
Johnson, MA
Haas, BJ
Loeschel, EA
Granier, C.
Jackson, F.
Pearce, HC
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P83
- URN
-
urn:nbn:de:1111-2016052053686
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rubio, R.
- Johnson, MA
- Haas, BJ
- Loeschel, EA
- Granier, C.
- Jackson, F.
- Pearce, HC
- SpringerLink (Online service)
Other Objects (12)
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701
I: Nr. 5701 - 9290
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701
I: Nr. 5701 - 9290
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701